key: cord-1010791-y02arv25 authors: Sainsbury, Christopher; Wang, Jingya; Gokhale, Krishna; Acosta‐Mena, Dionisio; Dhalla, Samir; Byne, Nathan; Chandan, Joht Singh; Anand, Astha; Cooper, Jennifer; Okoth, Kelvin; Subramanian, Anuradhaa; Bangash, Mansoor N; Taverner, Thomas; Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Cheng, Kar Keung; Marshall, Tom; Gkoutos, Georgios; Toulis, Konstantinos; Thomas, Neil; Tahrani, Abd; Adderley, Nicola J; Haroon, Shamil; Nirantharakumar, Krishnarajah title: Sodium‐glucose‐co‐transporter‐2 inhibitors and susceptibility to COVID‐19: a population‐based retrospective cohort study date: 2020-09-29 journal: Diabetes Obes Metab DOI: 10.1111/dom.14203 sha: 56f2f2c77b3e1f06b62193906ff0db24e50ce523 doc_id: 1010791 cord_uid: y02arv25 Sodium/glucose co‐transporter‐2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID‐19, when compared with an active comparator. We performed a propensity score‐matched cohort study with active comparators and a negative control outcome in a large UK‐based primary care dataset. Participants prescribed SGLT2i (n = 9948) and a comparator group prescribed dipeptyl‐peptidase 4 inhibitors (DPP4i; n = 14 917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID‐19. The incidence rate of COVID‐19 was 19.7/1000 person‐years among users of SGLT2i and 24.7/1000 person‐years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID‐19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID‐19 pandemic. This article is protected by copyright. All rights reserved. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in December 2019 in the district of Wuhan, China. The consequent multi-system illness (COVID-19) was particularly severe in older adults and those with comorbidities 1 , including diabetes 2 . The potential impact of drugs commonly used in diabetes on susceptibility to SARS-CoV-2 infection is of significant clinical and public health interest 3, 4 . Sodium/glucose co-transporter-2 inhibitors (SGLT2i) have an established beneficial impact on cardiovascular risk, blood pressure, chronic kidney disease progression and body weight 5 . They are associated with promotion of ACE2 activity, which may facilitate viral entry into cells, thereby increasing the susceptibility to clinically evident disease. They may also however provide a degree of protection via favourable impact on glycaemic control and inflammation 6 . Given the adverse outcomes associated with COVID-19 in the context of diabetes, and the uncertainty surrounding underlying mechanisms, an investigation of the potential for these commonly prescribed medications to influence presentation and course of COVID-19 is of importance. Current practice guidelines and expert opinion recommend that SGLT2i is discontinued in the community during acute illness and on hospital admission due to the increased risk of diabetic ketoacidosis 7, 8 . However, there is currently no This article is protected by copyright. All rights reserved. empirical evidence that use of SGLT2i increases the risk of developing COVID-19 among people with type 2 diabetes in the primary care setting. We aimed to investigate the risk of a composite of confirmed or suspected COVID-19 in people with type 2 diabetes prescribed SGLT2i, to a propensity score matched cohort of individuals prescribed a dipeptidyl peptidase-4 inhibitor (DPP4i) as an active comparator in primary care. This article is protected by copyright. All rights reserved. Further methodological detail can be found in Appendix 1. Study design: A population-based retrospective cohort study of people with type 2 diabetes comparing users of SGLT2i to propensity score-matched users of DPP4i.Data source: Data for this cohort study was derived from The Health Improvement Network (THIN), a database of routinely collected primary care records which is generalisable to the UK population. In 2020, it included data from 365 practices with approximately 2.1 million active patients. To improve data quality, general practices were eligible to be included in this study 12 months after the installation of Vision software and 12 months after reporting acceptable mortality rates 9 Study population: Individuals aged ≥18 years with a diagnosis of type 2 diabetes and registered with an eligible general practice for ≥1 year on the index date (30 th January 2020) were included. Patient diagnosed with diabetes before 12 years old, with a record of type 1 diabetes, pancreatitis, adverse reaction to antidiabetic agents at any time point, or pregnancy in the preceding year, were excluded. Exposure: Current users of SGLT2i or DPP4i were defined as individuals with a record of prescription lasting beyond the index date. People with type 2 diabetes with a current prescription of SGLT2i (exposed group) were compared to individuals with a current prescription of DPP4i (comparator This article is protected by copyright. All rights reserved. group). Neither cohort had a current prescription of the comparator medication. DPP4i was chosen as they are safe in the long-term management of people with diabetes 10 , and are actively recommended as a first intensification step 11 . Exposed and comparator groups were mutually exclusive. Matching: On the index date, participants in the exposed group was propensity score-matched to participants in the comparator group. Propensity score for use of SGLT2i was estimated using a logistic regression model including a set of covariates described in the covariates section below. Follow-up period: Participants were followed up from the 30 th January 2020 (index date) until the earliest of the following dates: date of the outcome, death, patient left practice, practice ceased contributing to the database, or study end date (22 nd July 2020). Outcomes: Primary outcome was a composite of confirmed or suspected diagnosis of COVID-19. Secondary outcomes were confirmed diagnosis of COVID-19 and COVID-19-related death. COVID-19 related death was defined as individuals whose death dates were not later than 28 days after occurrence of the primary outcome. We used a negative control outcome -incident back pain -during follow-up to assess the possibility of surveillance bias and unobserved confounding 12 . All outcomes were defined using the relevant clinical (Read) codes (Supplementary Table 1 ). This article is protected by copyright. All rights reserved. For a full list of covariates, please see Appendix 1. Statistical Analysis: Crude incidence rates per 1,000 person-years of COVID-19 and the negative control outcome, back pain, were estimated for the exposed and the comparator cohort. A Cox proportional hazards regression model was used to determine crude and adjusted hazard ratios (HR) for SGLT2i compared to DPP4i for the COVID-19 outcome and the negative control outcome. Survival curves for the exposed and the unexposed groups were generated for the unmatched and the propensity score matched cohorts. ,948 eligible people with type 2 diabetes with a current prescription for SGLT2i, and 14,917 people with a current prescription for DPP4i were identified. Baseline Characteristics: In the unmatched cohort, the SGLT2i cohort were younger, had a greater proportion of males, a higher mean BMI, a higher proportion of current smokers and a higher prevalence of excess alcohol use than the DPP4i cohort (Supplementary Table 4 ). This article is protected by copyright. All rights reserved. Figure 1) was observed in the SGLT2i compared to the DPP4i cohort. During the same period, in the unmatched group the crude incidence rate for developing back pain (negative control) was 10.7 per 1000 person years in the exposed group compared to 8.8 per 1000 person years in the comparator group. This translated to an adjusted HR of 1.11 (95% CI 0.72-1.72; Supplementary Table 5 ). This article is protected by copyright. All rights reserved. Following propensity score matching, 69 individuals in the exposed group (current SGLT2i users only) and 72 individuals in the comparator group (current DPP4i users only) were diagnosed with a composite of confirmed or suspected COVID-19, corresponding to crude incidence rates of 19.1 and 19.9 per 1000 person-years, respectively (Supplementary Table 5 ; Supplementary Figure 1 ). There were 15 individuals with a record of confirmed COVID-19 and one COVID-19 related death in the exposed group and 18 individuals with a record of confirmed COVID-19 and four COVID-19 related death in the comparator group (current DPP4i users only). No statistically significant difference in risk of primary care consultation for a composite of confirmed or suspected COVID-19 (adjusted HR 0.92, 95% CI 0.66 to 1.29) or confirmed COVID-19 (adjusted HR 0.78, 95% CI 0.39 to 1.56; Figure 1 ) was observed in the SGLT2i compared to the DPP4i cohort. When examining the rate of developing back pain in this cohort, the crude incidence rates of 11.4 and 8.6 per 1000 person-years, respectively for the exposed and comparator groups (Supplementary Table 5 ). This related to a non-statistically significant difference in risk between the groups (adjusted HR 1.22; 95% CI 0.76-1.96). Given the limited number of events for COVID-19 related death hazard ratios were not calculated. This article is protected by copyright. All rights reserved. This is the first study to explore the relationship between SGLT2i use and the risk of developing COVID-19. After adjusting for a number of potential confounders, and accounting for confounding by indication bias, we found no significant association between use of SGLT2i and primary care consultation for confirmed or suspected COVID-19 infection, when compared to use of DPP4i in a large primary care cohort of people with type 2 diabetes. Type 2 diabetes has been identified as a predictor of severe COVID-19, and poor glycaemic control is associated with increased risk of severe COVID-19 and mortality 2, 13 . However, information regarding which specific glucose lowering agents can be used to safely maintain or improve glycaemic control in the midst of the COVID-19 pandemic is currently limited 14 . Our study found no evidence that SGLT2i alter the risk of developing COVID-19. This helps to provide reassurance that these drugs can be used safely in primary care. There have been case reports of people with diabetes and COVID-19 presenting with euglycaemic ketoacidosis. SGLT2i selectively reduces interstitial volume and may exert anti-inflammatory effects 15 , which could further influence outcomes from COVID-19. The current recommendation of stopping SGLT2i when admitted to hospital should be therefore still be followed in people with type 2 diabetes and This article is protected by copyright. All rights reserved. This study has a number of limitations. Data quality is reliant on the coding practices of primary care clinicians and administrators. Individuals who present to primary care are more likely to be symptomatic rather than asymptomatic, and this group is likely therefore to be underrepresented. We did not have access to data on hospitalisation, inpatient management, ethnicity or socioeconomic status. There were a relatively small number of outcome events. The study also has important strengths. We attempted to minimise the effect of the differences in baseline characteristics between groups, as well as confounding by indication bias, by using a propensity score matched design. Levels of missingness were low. This resulted in robust comparisons of similar individuals in the primary analysis. We have adjusted for a large number of potential confounders, with analyses repeated using a negative control. This study adds to the understanding of COVID-19 management in the primary care setting. Our findings show no evidence that SGLT2i influences susceptibility to developing COVID-19 among people with type 2 diabetes in the primary care setting. These results are reassuring and suggest that clinicians can use these agents to improve glycaemic control in people with type 2 diabetes in the primary care setting during the COVID-19 pandemic, particularly given that hyperglycaemia is a poor prognostic outcome of COVID-19. This article is protected by copyright. All rights reserved. DPP4i=dipeptidyl peptidase-4 inhibitors, HR=hazard ratio, SGLT2i=sodium-glucose co-transporter-2 inhibitors Cohort 1:SGLT2i vs DPP4i COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients Type 1 and Type 2 Diabetes and COVID-19 Related Mortality in England: A Whole Population Study Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era Practical recommendations for the management of diabetes in patients with COVID-19 Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes The importance of defining periods of complete mortality reporting for research using automated data from primary care Is DPP4 inhibition a comrade or adversary in COVID-19 infection National Institute for Health and Care Excellence. Type 2 diabetes in adults: management NICE guideline Negative control exposure studies in the presence of measurement error: implications for attempted effect estimate calibration Type 1 and Type 2 Diabetes and COVID-19 Related Mortality in England: A Cohort Study in People with Diabetes Drugs and the renin-angiotensin system in covid-19